1.
Acta Pharmaceutica Sinica B
; (6): 3120-3133, 2021.
Artigo
em Inglês
| WPRIM (Pacífico Ocidental)
| ID: wpr-922784
RESUMO
ERK pathway regulated the programmed death ligand-1 (PD-L1) expression which was linked to the response of programmed death-1 (PD-1)/PD-L1 blockade therapy. So it is deducible that ERK inhibitor could enhance the efficacy of PD-1 inhibitor in cancer immunotherapy. In this study, PD0325901, an oral potent ERK inhibitor, strongly enhanced the efficacy of PD-1 antibody